Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte precursor cell | 6 studies | 37% ± 9% | |
precursor B cell | 3 studies | 30% ± 10% |
Insufficient scRNA-seq data for expression of BEST3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 92% | 286.66 | 2429 / 2642 | 96% | 19.71 | 678 / 705 |
muscle | 100% | 4871.46 | 803 / 803 | 0% | 0 | 0 / 0 |
adrenal gland | 62% | 63.47 | 159 / 258 | 10% | 0.38 | 22 / 230 |
prostate | 44% | 87.15 | 107 / 245 | 22% | 0.41 | 109 / 502 |
kidney | 6% | 4.76 | 5 / 89 | 9% | 0.14 | 85 / 901 |
breast | 12% | 15.17 | 55 / 459 | 3% | 0.08 | 31 / 1118 |
skin | 13% | 17.72 | 229 / 1809 | 1% | 0.01 | 3 / 472 |
pancreas | 8% | 6.13 | 25 / 328 | 4% | 0.08 | 8 / 178 |
tonsil | 0% | 0 | 0 / 0 | 9% | 0.22 | 4 / 45 |
lymph node | 0% | 0 | 0 / 0 | 7% | 0.22 | 2 / 29 |
stomach | 0% | 0 | 0 / 359 | 6% | 0.55 | 18 / 286 |
heart | 5% | 4.96 | 45 / 861 | 0% | 0 | 0 / 0 |
bladder | 0% | 0 | 0 / 21 | 5% | 0.46 | 24 / 504 |
esophagus | 1% | 4.25 | 13 / 1445 | 4% | 0.12 | 7 / 183 |
uterus | 0% | 0 | 0 / 170 | 5% | 0.46 | 21 / 459 |
intestine | 0% | 0.12 | 1 / 966 | 4% | 0.19 | 22 / 527 |
thymus | 1% | 2.54 | 7 / 653 | 3% | 0.05 | 16 / 605 |
lung | 0% | 0 | 0 / 578 | 3% | 0.17 | 38 / 1155 |
liver | 0% | 0 | 0 / 226 | 2% | 0.03 | 9 / 406 |
peripheral blood | 2% | 1.79 | 18 / 929 | 0% | 0 | 0 / 0 |
adipose | 1% | 1.23 | 11 / 1204 | 0% | 0 | 0 / 0 |
ovary | 0% | 0 | 0 / 180 | 1% | 0.01 | 3 / 430 |
blood vessel | 0% | 3.73 | 6 / 1335 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_1902476 | Biological process | chloride transmembrane transport |
GO_0008150 | Biological process | biological_process |
GO_0043271 | Biological process | negative regulation of monoatomic ion transport |
GO_0034707 | Cellular component | chloride channel complex |
GO_0005886 | Cellular component | plasma membrane |
GO_0099095 | Molecular function | ligand-gated monoatomic anion channel activity |
GO_0005229 | Molecular function | intracellularly calcium-gated chloride channel activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0003674 | Molecular function | molecular_function |
Gene name | BEST3 |
Protein name | Bestrophin Bestrophin-3 (Vitelliform macular dystrophy 2-like protein 3) |
Synonyms | VMD2L3 |
Description | FUNCTION: Forms calcium-sensitive chloride channels. Permeable to bicarbonate. . FUNCTION: Forms calcium-sensitive chloride channels. Permeable to bicarbonate. . FUNCTION: Forms calcium-sensitive chloride channels. Permeable to bicarbonate. . FUNCTION: Forms calcium-sensitive chloride channels. Permeable to bicarbonate. . FUNCTION: Forms calcium-sensitive chloride channels. Permeable to bicarbonate. . |
Accessions | ENST00000266661.8 [Q8N1M1-4] F8VR37 Q8N1M1 ENST00000476098.5 ENST00000553096.5 [Q8N1M1-6] F8VVX2 F8VZR0 ENST00000488961.5 [Q8N1M1-5] ENST00000551160.5 [Q8N1M1-4] ENST00000547208.5 ENST00000548658.1 ENST00000330891.10 [Q8N1M1-2] E9PNM2 ENST00000552295.5 ENST00000331471.8 [Q8N1M1-1] |